Table 1.
Follow-up of oCD and HIV-RCD clinical groups by qPCR and Tc-LAMP.
| Clinical Group | ID Patient | Gender (F/M) | Age (years) | Pathology/Laboratory/CNS Imaging Findings at Diagnosis | Sample Type | Sample ID | Time from Treatment Initiation | # Mean Parasite Load (par.eq/mL) | § qPCR Result | Tc-LAMP Spin-Column | Tc-LAMP PrintrLab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OraL Chagas disease | oCD1 | M | 16 | At the time of confirming the case (2009), IgM and IgG serology postive and no evidence of cardiac abnormality due to acute phase. Treatment with benznidazole 7 mg/kg/day for 60 days | GEB | oCD1.1 | 0 | 5.13 | Positive | Positive | NP |
| oCD1.2 | 12 m | 1.97 | Positive | Positive | NP | ||||||
| oCD1.3 | 24 m | NAR | Negative | Negative | NP | ||||||
| oCD2 | M | 8 | At the time of confirming the case (2009), IgM and IgG serology postive. abnormal EKG. Treatment with benznidazole 7 mg/kg/day for 60 days. | GEB | oCD2.1 | 0 | 14.87 | Positive | Positive | Positive | |
| oCD2.2 | 36 m | 1.75 | Positive | Positive | NP | ||||||
| oCD2.3 | 108 m | 1.6 | Positive | Positive | NP | ||||||
| oCD3 | F | 9 | At the time of confirming the case (2009), IgM positive and IgG negative. abnormal EKG. Treatment with benznidazole 7 mg/kg/day for 60 days | GEB | oCD3.1 | 0 | 4586.77 | Positive | Positive | NP | |
| oCD3.2 | 6 m | 3521.09 | Positive | Positive | NP | ||||||
| oCD3.3 | 24 m | 2258.83 | Positive | Positive | NP | ||||||
| oCD4 | M | 36 | At the time of confirming the case (2009), IgM and IgG serology postive. abnormal EKG. Treatment with benznidazole 7 mg/kg/day for 60 days. | GEB | oCD4.1 | 0 | 1733.56 | Positive | Positive | NP | |
| oCD4.2 | 36 m | 1842.84 | Positive | Positive | NP | ||||||
| oCD4.3 | 108 m | 1172.27 | Positive | Positive | NP | ||||||
| OCD5 | F | 7 | At the time of confirming the case (2009), IgM and IgG serology postive. abnormal EKG. Treatment with benznidazole 7 mg/kg/day for 60 days. | GEB | oCD5.1 | 0 | 0.35 | Positive | Negative | NP | |
| oCD5.2 | 36 m | NAR | Negative | Negative | NP | ||||||
| oCD5.3 | 60 m | 5 | Positive | Positive | NP | ||||||
| OCD6 | F | 9 | At the time of confirming the case (2009), IgM aad IgG serology postive. abnormal EKG. Strout positive Treatment with benznidazole 7 mg/kg/day for 60 days. | GEB | oCD6.1 | 0 | 0.35 | Positive | Positive | NP | |
| oCD6.2 | 36 m | 5.56 | Positive | Positive | Positive | ||||||
| oCD6.3 | 60 m | 14.99 | Positive | Negative | Positive | ||||||
| oCD7 | F | 10 | At the time of confirming the case (2009), IgM and IgG serology postive. abnormal EKG. Treatment with benznidazole 7 mg/kg/day for 60 days | GEB | oCD7.1 | 12 m | 1.75 | Positive | Positive | Positive | |
| oCD7.2 | 108 m | 2.93 | Positive | Positive | NP | ||||||
| oCD8 | F | 11 | At the time of confirming the case (2009), IgM and IgG serology postive. abnormal EKG. Treatment with benznidazole 7 mg/kg/day for 60 days | GEB | oCD8.1 | 60 m | 2697.31 | Positive | Positive | NP | |
| oCD8.2 | 108 m | 1126.81 | Positive | Positive | NP | ||||||
| oCD9 | F | 8 | At the time of confirming the case (2009), IgM and IgG serology postive aNP no evidence of cardiac abnormality due to acute phase. Treatment with benznidazole 7 mg/kg/day/day for 60 days | GEB | oCD9.1 | 24 m | 2404.02 | Positive | Positive | NP | |
| oCD9.2 | 60 m | NAR | Negative | Negative | NP | ||||||
| AIDS-Chagas Reactivation | HIV-RCD1 | M | 42 | Seizures/encephalitis with two space-occupying lesions CD4 7 cells/mL, Trypomastigotes in CSF | EB | HIV-RCD1.1 | 0 | 107 | Positive | Positive | Positive |
| HIV-RCD1.2 | 5 d | 2 | Positive | Positive | NP | ||||||
| HIV-RCD1.3 | 14 d | NAR | Negative | Negative | NP | ||||||
| HIV-RCD2 | M | 55 | Sensory impairment/marked cerebral cortex atrophy; encephalitis with two space- occupying lesion CD4 10 cells/mL. Trypomastigotes in CSF | CSF | HIV-RCD2.1 | 0 | 3511.5 | Positive | Positive | NP | |
| CSF | HIV-RCD2.2 | 7 d | 13556 | Positive | Positive | NP | |||||
| EB | HIV-RCD2.3 | 14 d | NAR | Negative | Negative | Negative | |||||
| HIV-RCD3 | F | 39 | Right Hemiparesis, faciobrachiocrural/encephalytis with large space occupying lesion aNP brain midline shift CD4 10 cells/mL Strout Positive | EB | HIV-RCD3.1 | 0 | 677 | Positive | Positive | NP | |
| HIV-RCD3.2 | 24 d | 12,7 | Positive | Positive | NP | ||||||
| HIV-RCD3.3 | 38 d | NAR | Negative | Positive | NP |
Grey boxes indicate the samples collected since initiation of treatment. No samples at initiation of treatment were available for oCD7-9. Tx: transplant, F: female; M: male; d, days; m, months; GEB: guanidine-EDTA Blood; EB: EDTA blood; CSF: cerebrospinal fluid; par.eq./mL: parasite equivalents per millilitre of sample; NA: not applicable; NAR: no amplification reaction, NP: not performed. # Parasite loads were measured in the original samples during the patients’ follow-up. §: Qualitative qPCR results correspond to the archival paired sample retested by qPCR at the time Tc-LAMP was carried out in archival samples.